Abstract
Biomarkers of progression to severe dengue are urgently required for effective patient management. Innate immune cells have been implicated in the enhancement of infection and “cytokine storm” associated with dengue severity. Using intracellular cytokine staining and flow cytometry, we observed significantly higher proportions of innate immune cells secreting inflammatory cytokines dominated by IFN-γ and TNF-α at admission associated with good prognosis. Secondary dengue predisposed to severe outcomes. In patients with severe dengue and those with liver impairment, early activation as well as efficient down-regulation of innate responses were compromised. IFN-γ+CD56+CD3+ NKT cells and IL-6+ granulocytes served as novel biomarkers of progression to severity (composite AUC=0.85-0.9). Strong correlations among multiple cytokine-secreting innate cell subsets pointed to coordinated activation of the entire innate immune system by DENV.
One Sentence Summary Activation and efficient attenuation of innate immunity are both compromised in severe dengue.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Funding: This work was funded by Rajiv Gandhi University of Health Sciences (Grant number: RGU/ADV.RES/016/2017-2018). The funding agency had no role in the study.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was carried out in accordance with the Declaration of Helsinki. Institutional ethics committee approval to conduct the study was obtained from the four participating hospitals; Bangalore Medical College and Research Institute (BMCRI; BMCRI/PS/25/2018-19), Kempegowda Institute of Medical Sciences (KIMS; KIMS/IEC/A1-2018), St. Johns Medical College (SJMC; IEC/1/473/2019), M S Ramaiah Medical College (RMCH; MSRMC/EC/19) and Indian Institute of Science (IISc; 10-14032018), Bengaluru, India.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data and materials availability: All data are available in the supplementary materials. De-identified flow cytometry files (.fcs) that support the results reported in this article, and analyzed flow cytometry data (.xlsx) will be made available on request.
